

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON THE DATE INDICATED BELOW.

By: Helene Gabel Date: January 18, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Patent Application of:
Ye Wu *et al.*

Conf. No.:	4224	:	Group Art Unit:	1624
Appln. No.:	10/627,483	:	Examiner:	Thomas C. McKenzie, Ph.D.
Filing Date:	July 25, 2003	:	Attorney Docket No.:	066131-53U1 (formerly X-0219)

Title: PROCESS FOR SYNTHESIZING ANTIFOLATES

REVOCATION AND APPOINTMENT OF ATTORNEY BY ASSIGNEE

The undersigned states that he is authorized to sign the document on behalf of the assignee of the above application, that the evidentiary documents relating to the assignment of the above application have been reviewed, and he certifies that, to the best of assignee's knowledge and belief, title to the above application is in assignee by virtue of an assignment recorded in the U.S. Patent and Trademark Office on July 25, 2003 under Reel 014347, Frame 0069.

BioNumerik Pharmaceuticals, Inc., assignee of the above application, by its undersigned representative, hereby revokes all previous Powers of Attorney and appoints the registered attorneys and agents associated with Customer No. 000570, Akin Gump Strauss Hauer & Feld LLP, as its attorneys or agents with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Please address all correspondence to **Customer No. 000570, namely, AKIN GUMP STRAUSS HAUER & FELD LLP**, One Commerce Square, 2005 Market Street, Suite 2200,


Philadelphia, Pennsylvania 19103-7013. Please direct all communications and telephone calls to Alan S. Nadel at 215-965-1280 (telephone) or 215-965-1210 (facsimile).

Respectfully submitted,
BioNumerik Pharmaceuticals, Inc.

December 22, 2004

Date

By:



Frederick H. Hausheer, M.D.
Chief Executive Officer